Artiva Biotherapeutics Stock Soars: Wedbush Raises Price Target to $23 on Breakthrough RA Treatment
Wedbush upgrades Artiva Biotherapeutics price target to $23 citing FDA Fast Track for AlloNK therapy targeting refractory rheumatoid arthritis with potential 2026 pivotal trial.